P2B001 Research Study

P2B001: a slow-release drug for Parkinson’s diseaseПодробнее

Parkinson's Disease- Medical Research Study- May 19, 2022Подробнее

Participating in Parkinson's Disease Research StudiesПодробнее

RDM Workshop: Case Study 1 mPower and Parkinson's Disease & Panel DiscussionПодробнее

The Role of Research in Parkinson'sПодробнее

PADOVA study: prasinezumab in patients with early Parkinson's diseaseПодробнее

Parkinson's Disease:- "Drug research & development review" by Dr Kevin McFarthingПодробнее

Phase III trial update of P2B001 for Parkinson's diseaseПодробнее

New Parkinson's Therapy P2B001 Shows Similar Efficacy to Mirapex with Fewer Side Effects #shortsПодробнее

Searching for Early Detection of Parkinson'sПодробнее

New Parkinson Disease Clinical Trial: Citalopram 20mg for Parkinson DiseaseПодробнее

2022 Parkinson's Disease Research UpdateПодробнее

Phase II study of risvodetinib in Parkinson's diseaseПодробнее

Parkinson’s Research - Patient Perspectives: Marilyn Guidinger, PhDПодробнее

What have clinical trials taught us about Parkinson's disease?Подробнее

New Research: Cause, Progression and Diagnosis of Parkinson's DiseaseПодробнее

Research advancements in the pathogenesis of Parkinson’s diseaseПодробнее

Pitt/UPMC Research Study WebinarПодробнее

New Frontiers in Parkinson's Disease Research and Care - WestchesterПодробнее